Uppsala Clinical Research Center—development of a platform to promote national and international clinical science

by Lars Wallentin, Bertil Lindahl
Published 2019-01-01

Genome-Wide Association Study Identifies That the ABO Blood Group System Influences Interleukin-10 Levels and the Risk of Clinical Events in Patients with Acute Coronary Syndrome.

by Åsa Johansson, Jenny Alfredsson, Niclas Eriksson, Lars Wallentin, Agneta Siegbahn
Published 2015-01-01

GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men.

by Lars Wallentin, Björn Zethelius, Lars Berglund, Kai M Eggers, Lars Lind, Bertil Lindahl, Kai C Wollert, Agneta Siegbahn
Published 2013-01-01

Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome?

by Diana Ernst, Christian Widera, Niklas T. Baerlecken, Wolfgang Schlumberger, Cornelia Daehnrich, Reinhold E. Schmidt, Katja Gabrysch, Lars Wallentin, Torsten Witte
Published 2017-11-01

Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis

by Bakhtawar K. Mahmoodi, Niclas Eriksson, Gerrit J. A. Vos, Karina Meijer, Agneta Siegbahn, Stefan James, Lars Wallentin, Jurriën M. ten Berg
Published 2021-06-01

Angina, "normal" coronary angiography, and vascular dysfunction: risk assessment strategies.

by Raffaele Bugiardini, Lina Badimon, Peter Collins, Raimund Erbel, Kim Fox, Christian Hamm, Fausto Pinto, Annika Rosengren, Christodoulos Stefanadis, Lars Wallentin, Frans Van de Werf
Published 2007-02-01

Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study.

by Finlay A McAlister, Rajibul Mian, Jonas Oldgren, Lars Wallentin, Michael Ezekowitz, Salim Yusuf, Stuart J Connolly, Jeff S Healey, RE-LY Atrial Fibrillation Registry Investigators
Published 2020-01-01

Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials

by Bakhtawar K. Mahmoodi, Niclas Eriksson, Stephanie Ross, Daniel M. F. Claassens, Folkert W. Asselbergs, Karina Meijer, Agneta Siegbahn, Stefan James, Guillaume Pare, Lars Wallentin, Jurriën M. ten Berg
Published 2021-09-01

Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study.

by Lars Wallentin, Niclas Eriksson, Maciej Olszowka, Tanja B Grammer, Emil Hagström, Claes Held, Marcus E Kleber, Wolfgang Koenig, Winfried März, Ralph A H Stewart, Harvey D White, Mikael Åberg, Agneta Siegbahn
Published 2021-01-01

ProteinSeq: high-performance proteomic analyses by proximity ligation and next generation sequencing.

by Spyros Darmanis, Rachel Yuan Nong, Johan Vänelid, Agneta Siegbahn, Olle Ericsson, Simon Fredriksson, Christofer Bäcklin, Marta Gut, Simon Heath, Ivo Glynne Gut, Lars Wallentin, Mats G Gustafsson, Masood Kamali-Moghaddam, Ulf Landegren
Published 2011-01-01

Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.

by Astrid Yeo, Li Li, Liling Warren, Jennifer Aponte, Dana Fraser, Karen King, Kelley Johansson, Allison Barnes, Colin MacPhee, Richard Davies, Stephanie Chissoe, Elizabeth Tarka, Michelle L O'Donoghue, Harvey D White, Lars Wallentin, Dawn Waterworth
Published 2017-01-01

Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery

by Sean vanDiepen, Pierluigi Tricoci, Mohua Podder, Cynthia M. Westerhout, Philip E. Aylward, Claes Held, Frans Van de Werf, John Strony, Lars Wallentin, David J. Moliterno, Harvey D. White, Kenneth W. Mahaffey, Robert A. Harrington, Paul W. Armstrong
Published 2015-12-01

Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk.

by Ingrid Brænne, Lingyao Zeng, Christina Willenborg, Vinicius Tragante, Thorsten Kessler, CARDIoGRAM Consortium, CARDIoGRAMplusC4D Consortium, Cristen J Willer, Markku Laakso, Lars Wallentin, Paul W Franks, Veikko Salomaa, Abbas Dehghan, Thomas Meitinger, Nilesh J Samani, Folkert W Asselbergs, Jeanette Erdmann, Heribert Schunkert
Published 2017-01-01

Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease.

by Ani Manichaikul, Xin-Qun Wang, Li Li, Jeanette Erdmann, Guillaume Lettre, Joshua C Bis, Dawn Waterworth, Mary Cushman, Nancy S Jenny, Wendy S Post, Walter Palmas, Michael Y Tsai, Lars Wallentin, Harvey White, Heribert Schunkert, Christopher J O'Donnell, David M Herrington, Stephen S Rich, Michelle L O'Donoghue, Annabelle Rodriguez
Published 2018-01-01

Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Even...

by Meena P. Rao, Sigrun Halvorsen, Daniel Wojdyla, Laine Thomas, John H. Alexander, Elaine M. Hylek, Michael Hanna, M. Cecilia Bahit, Renato D. Lopes, Raffaele De Caterina, Cetin Erol, Shinya Goto, Fernando Lanas, Basil S. Lewis, Steen Husted, Bernard J. Gersh, Lars Wallentin, Christopher B. Granger, the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators
Published 2015-12-01